Novartis CEO: Don't expect us to slay Vasella's pets

Tools
CEO Joe Jimenez

With a new chairman selected to take the helm of Novartis ($NVS), lots of folks are wondering what is in store for the Swiss drugmaker. Not so fast, CEO Joe Jimenez said this week. Just because former Chairman Daniel Vasella has left, don't expect the Swiss company to just up and sell its $12 billion stake in Roche ($RHHBY), the accumulation of which was a pet project of Vasella, Reuters reports. And while he was at it, the CEO swatted back talk that Novartis might want to sell its vaccine business, which also came to the Swiss drug giant on Vasella's watch. FiercePharma's Report

Filed Under